BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

Genetic alterations in the kinase domain of the epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) patients are associated with sensitivity to treatment with small molecule tyrosine kinase inhibitors. Although first-generation reversible, ATP-competitive inhibitors showed...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Li, D, Ambrogio, L, Shimamura, T, Kubo, S, Takahashi, M, Chirieac, LR, Padera, RF, Shapiro, GI, Baum, A, Himmelsbach, F, Rettig, WJ, Meyerson, M, Solca, F, Greulich, H, Wong, K-K
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2008
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2748240/
https://ncbi.nlm.nih.gov/pubmed/18408761
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2008.109
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi